JO
LJPC

John Overdeck’s La Jolla Pharmaceutical Company LJPC Stock Holding History

John Overdeck’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,544
Closed -$118K – 3175
2022
Q1 		$118K Sell
27,544
-60,632
-69% -$264K ﹤0.01% 2414
2021
Q4 		$410K Sell
88,176
-28,918
-25% -$121K ﹤0.01% 3430
2021
Q3 		$467K Sell
117,094
-16,478
-12% -$65.4K ﹤0.01% 3328
2021
Q2 		$572K Sell
133,572
-115,709
-46% -$496K ﹤0.01% 2976
2021
Q1 		$1.06M Buy
249,281
+26,203
+12% +$144K ﹤0.01% 2262
2020
Q4 		$866K Buy
223,078
+35,402
+19% +$151K ﹤0.01% 2116
2020
Q3 		$756K Sell
187,676
-90,183
-32% -$374K ﹤0.01% 1955
2020
Q2 		$1.18M Buy
277,859
+205,068
+282% +$1.25M 0.01% 1427
2020
Q1 		$306K Buy
+72,791
New +$460K ﹤0.01% 2290

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

John Overdeck's LJPC Position: Q2 2022 in Review

John Overdeck sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2022, closing a stake of 27,544 shares — an estimated $118K sold.

John Overdeck first reported a position in LJPC in Q1 2020 and held it in 9 quarters. The position peaked at $1.18M in Q2 2020. 41 funds tracked by Wall St. Rank hold LJPC as of Q2 2022.

  • John Overdeck reported no remaining La Jolla Pharmaceutical Company position as of Q2 2022 after selling out during the quarter.
  • John Overdeck sold 27,544 La Jolla Pharmaceutical Company shares in Q2 2022, an estimated $118K.
  • John Overdeck first reported a position in La Jolla Pharmaceutical Company in Q1 2020 and held it in 9 quarters.
  • John Overdeck's La Jolla Pharmaceutical Company position peaked at $1.18M in Q2 2020.
  • 41 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.